Holen Sie sich die Stockscreener-App
9.66
0.95%
0.19
Handel nachbörslich:
9.66
Schlusskurs vom Vortag:
$9.47
Offen:
$9.18
24-Stunden-Volumen:
116.03K
Relative Volume:
1.59
Marktkapitalisierung:
$51.69M
Einnahmen:
$7.97M
Nettoeinkommen (Verlust:
$-75.74M
KGV:
-0.3978
EPS:
-24.2853
Netto-Cashflow:
$-85.33M
1W Leistung:
-2.85%
1M Leistung:
-6.27%
6M Leistung:
+107.38%
1J Leistung:
+32.23%
1-Tages-Spanne:
$9.02
$9.66
1-Wochen-Bereich:
$9.02
$10.36
52-Wochen-Spanne:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Firmenname
Aligos Therapeutics Inc
Sektor
Branche
Telefon
(800) 466-6059
Adresse
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Vergleichen Sie ALGS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
9.66 | 65.83M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-01-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-01-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-09 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-10 | Eingeleitet | Jefferies | Buy |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Aligos Therapeutics Inc Aktie (ALGS) Neueste Nachrichten
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference - The Manila Times
Will Aligos Therapeutics Inc. (5WK0) stock gain from green policiesGap Up & High Accuracy Investment Entry Signals - newser.com
Why Aligos Therapeutics Inc. stock appeals to dividend seekersWeekly Trade Report & Fast Entry Momentum Trade Alerts - newser.com
Why Aligos Therapeutics Inc. stock remains on buy listsWeekly Profit Summary & Reliable Intraday Trade Alerts - newser.com
Is Aligos Therapeutics Inc. stock positioned well for digital economy2025 Institutional Moves & Short-Term Trading Alerts - newser.com
Published on: 2025-10-13 09:41:36 - newser.com
How buybacks impact Aligos Therapeutics Inc. stock valueJuly 2025 Market Mood & High Return Trade Guides - newser.com
Is Aligos Therapeutics Inc. stock supported by strong fundamentalsTrade Risk Assessment & Weekly High Conviction Ideas - newser.com
Risk adjusted return profile for Aligos Therapeutics Inc. analyzedDip Buying & AI Enhanced Trading Alerts - newser.com
Is Aligos Therapeutics Inc. stock ready for a breakoutDip Buying & Intraday High Probability Setup Alerts - newser.com
Using data tools to time your Aligos Therapeutics Inc. exit2025 Fundamental Recap & AI Powered Trade Plan Recommendations - newser.com
Why Aligos Therapeutics Inc. is moving todayWeekly Trade Review & AI Enhanced Market Trend Forecasts - newser.com
How Aligos Therapeutics Inc. stock reacts to inflationary pressuresJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
Is Aligos Therapeutics Inc. stock bottoming outMarket Sentiment Review & Verified Momentum Watchlists - newser.com
What momentum shifts mean for Aligos Therapeutics Inc.Gold Moves & Real-Time Chart Breakout Alerts - newser.com
Does Aligos Therapeutics Inc. qualify in momentum factor screeningTrade Analysis Report & Community Consensus Trade Signals - newser.com
Aligos Therapeutics (NASDAQ:ALGS) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Published on: 2025-10-08 08:18:12 - earlytimes.in
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025 - Investing News Network
Aligos Therapeutics, Inc. Announces Eight Presentations at The Liver Meeting® 2025, Including Oral Presentation on Novel HBV Therapy - Quiver Quantitative
8 Abstracts Accepted — Aligos Presents Oral 96‑Week ALG-000184 HBV Data at The Liver Meeting 2025 - Stock Titan
Is Aligos Therapeutics Inc 5WK0 a good long term investmentStop Loss Placement Tips & High Profit Stock Alerts - earlytimes.in
Aligos Therapeutics reports new PD-1/PD-L1 interaction inhibitors - BioWorld MedTech
Is Aligos Therapeutics Inc. (5WK0) stock a fit for income portfoliosPortfolio Performance Report & Daily Volume Surge Trade Alerts - newser.com
How Aligos Therapeutics Inc. (5WK0) stock stacks up against competitorsJuly 2025 Final Week & Real-Time Stock Price Movement Reports - newser.com
How strong is Aligos Therapeutics Inc. stock balance sheetWeekly Trend Summary & Smart Money Movement Alerts - newser.com
How Aligos Therapeutics Inc. (5WK0) stock trades in high volatility2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com
Aligos Therapeutics Inc. stock daily chart insightsJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
What to do if you’re stuck in Aligos Therapeutics Inc.July 2025 Sector Moves & Fast Gain Stock Tips - newser.com
D pipeline2025 Big Picture & Real-Time Price Movement Reports - newser.com
Aligos Therapeutics (NASDAQ:ALGS) Shares Up 5% – Should You Buy? - Defense World
What drives First Tellurium Corp G1J stock priceTake Profit Strategies & Minimal Capital Trading Tips - earlytimes.in
Finanzdaten der Aligos Therapeutics Inc-Aktie (ALGS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):